• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Champions Oncology Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    7/21/25 1:49:17 PM ET
    $CSBR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $CSBR alert in real time by email
    csbr-20250721
    0000771856false00007718562025-07-212025-07-21


    UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549
     
     
    FORM 8-K
     
    CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF
    THE SECURITIES EXCHANGE ACT OF 1934
     
    Date of report (Date of earliest event reported): July 21, 2025
     
    CHAMPIONS ONCOLOGY, INC.
     
    (Exact name of registrant as specified in its charter)
     
    Delaware 001-11504 52-1401755
    (State or Other Jurisdiction (Commission File Number) (IRS Employer
    of Incorporation)   Identification No.)
     
    1 University Plaza, Suite 307, Hackensack, New Jersey 07601
    (Address of Principal Executive Offices)
     
    Registrant’s telephone number, including area code: (201) 808-8400
     
    N/A
    (Former Name or Former Address if Changed Since Last Report)
     
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
    ¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Exchange Act
    Title of Each ClassTrading Symbol(s)Name of Each Exchange on Which Registered
    Common Stock, par value $0.001 per shareCSBRThe Nasdaq Stock Market LLC
        

    Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company o

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o




    INFORMATION TO BE INCLUDED IN THE REPORT
     
    Item 5.02Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
     
    On July 18, 2025, Champions Oncology, Inc. (the “Company”) announced the hiring and appointment of Robert Brainin to serve as the Company’s Chief Executive Officer, effective as of August 25, 2025.

    Mr. Brainin, age 54, has served as a member of the Company's Board of Directors since February 2021 and will remain a Director following his appointment to Chief Executive Officer. He brings more than 25 years of experience in life sciences and technology. Most recently, Mr. Brainin served as Chief Business Officer and Executive Vice President at Veracyte, an oncology diagnostics company, since July 2021. From August 2017 to January 2021, he worked at Genuity Science, where he held various positions including Chief Executive Officer, Chief Operating Officer and served as a director. Before joining Genuity, he was Vice President and General Manager of Life Sciences and Applied Genomics at Illumina, and before that as a Vice President/General Manager of the Enterprise Genomics Solutions business of Thermo Fisher Scientific, Inc. He joined Thermo Fisher via its acquisition of Life Technologies, Inc. in 2014. From 2004 to 2014, Mr. Brainin served in a number of positions at Life Technologies and its predecessor, Invitrogen, predominantly leading a variety of large businesses that served customers in the academic and BioPharma segments. In all these roles, he led the expansion of the applications of technologies or genomic data to new fields to serve the needs of growing types of users. Earlier in his career, he was a management consultant at McKinsey & Co. and has served as an adjunct professor at the University of San Diego School of Law. Mr. Brainin holds an undergraduate degree in economics from Emory University and a law degree from Harvard Law School.

    Mr. Brainin has entered into an Employment Agreement (attached hereto as Exhibit 10.1). Pursuant to the agreement, he will receive an annual base salary of $500,000 and will have the opportunity to earn a discretionary target incentive bonus of 75% of his base salary. He will also receive multiple equity awards, including 225,000 options to purchase the Company’s common stock, which will vest over a four-year period, and 475,000 options to purchase the Company’s common stock which will vest at varying time points and are based on varying performance criteria.

    There are no family relationships between Mr. Brainin and any director or executive officer of the Company. There are no transactions between the Company and Mr. Brainin that are subject to disclosure under Item 404(a) of Regulation S-K.

    Ronnie Morris, M.D., will transition to Executive Chairman of the Board on August 25, 2025, supporting the leadership transition while remaining actively involved in the Company’s strategic initiatives. Joel Ackerman, Chairman of the Board, will transition to Board Director.

    A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein.

    Item 9.01.Financial Statements and Exhibits.
     
    (d)Exhibits
    The following exhibits are filed herewith:
     
    Exhibit No.
    99.1
    Press Release dated July 18, 2025
    10.1
    Employment Agreement between Champions Oncology, Inc. and Robert Brainin, effective as of July 16, 2025
     



    SIGNATURES
     
    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
     
      CHAMPIONS ONCOLOGY, INC.
      (Registrant)
       
    Date: July 21, 2025By:/s/ Joel Ackerman 
      Joel Ackerman 
      Chairman of the Board of Directors 
     

    Get the next $CSBR alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CSBR

    DatePrice TargetRatingAnalyst
    9/12/2024$6.00Hold → Buy
    Craig Hallum
    More analyst ratings

    $CSBR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Champions Oncology upgraded by Craig Hallum with a new price target

    Craig Hallum upgraded Champions Oncology from Hold to Buy and set a new price target of $6.00

    9/12/24 9:23:16 AM ET
    $CSBR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Roth Capital reiterated coverage on Champions Oncology with a new price target

    Roth Capital reiterated coverage of Champions Oncology with a rating of Buy and set a new price target of $16.00 from $13.50 previously

    3/15/21 10:03:32 AM ET
    $CSBR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CSBR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Mendelson Daniel Newman bought $6,500 worth of shares (1,000 units at $6.50), increasing direct ownership by 0.51% to 198,625 units (SEC Form 4)

    4 - CHAMPIONS ONCOLOGY, INC. (0000771856) (Issuer)

    1/16/24 11:45:44 AM ET
    $CSBR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Mendelson Daniel Newman bought $12,540 worth of shares (2,000 units at $6.27), increasing direct ownership by 1% to 197,625 units (SEC Form 4)

    4 - CHAMPIONS ONCOLOGY, INC. (0000771856) (Issuer)

    1/12/24 12:47:07 PM ET
    $CSBR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Mendelson Daniel Newman bought $18,577 worth of shares (2,944 units at $6.31), increasing direct ownership by 2% to 195,625 units (SEC Form 4)

    4 - CHAMPIONS ONCOLOGY, INC. (0000771856) (Issuer)

    1/11/24 10:57:35 AM ET
    $CSBR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CSBR
    SEC Filings

    View All

    SEC Form 10-K filed by Champions Oncology Inc.

    10-K - CHAMPIONS ONCOLOGY, INC. (0000771856) (Filer)

    7/23/25 5:01:48 PM ET
    $CSBR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Champions Oncology Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - CHAMPIONS ONCOLOGY, INC. (0000771856) (Filer)

    7/23/25 4:11:40 PM ET
    $CSBR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Champions Oncology Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - CHAMPIONS ONCOLOGY, INC. (0000771856) (Filer)

    7/21/25 1:49:17 PM ET
    $CSBR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CSBR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Champions Oncology Enhances Clinical Bioanalytical Services Portfolio with New Technology and Additional Leadership

    HACKENSACK, NJ / ACCESSWIRE / January 8, 2025 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading technology-enabled oncology research organization with specialty testing services, is excited to announce significant advancements in its bioanalytical services portfolio, specifically, expanding its capabilities with the integration of multiple global Cytek Aurora flow cytometers and the appointment of Troy Tremaine, MBA, to spearhead Bioanalytical Commercial Strategy.The addition of Cytek Aurora instruments elevates Champions' service offerings, building on its already competitive spectral and conventional flow cytometry capabilities. The continued investment in this clinical portfolio of serv

    1/8/25 8:00:00 AM ET
    $CSBR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Champions Oncology Reports Quarterly Revenue of $13.5 Million Adjusted EBITDA of $1.1 Million

    HACKENSACK, NJ / ACCESSWIRE / December 11, 2024 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, today announced its financial results for its second quarter of fiscal 2025, ended October 31, 2024.Second Quarter and Recent Highlights:Total revenue increased 17% to $13.5 millionGross profit of $6.1 million; margin of 45%Net income of approximately $730,000Adjusted EBITDA of $1.1 millionDevelopment of new data revenue streamFirst Half 2025 Highlights:Total revenue increased 14% to $27.6 millionGross profit of $13.1 million; margin of 47%Net income of $2.1 millionAdjusted EBITDA of $3.2 millionRonni

    12/11/24 4:00:00 PM ET
    $CSBR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Champions Oncology to Announce Second Quarter Financial Results on Wednesday, December 11, 2024

    HACKENSACK, NJ / ACCESSWIRE / December 5, 2024 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, will report its financial and operational results for the second quarter ended October 31, 2024, on Wednesday, December 11, 2024, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M. EST (1:30 P.M. PST). To join the call dial 888-506-0062 (Domestic) or 973-528-0011 (International) and enter the access code 710610. A replay of the call will be available by dialing 877-481-4010 (Domestic) or 919-882-2331 (International) and entering passcode: 51750, or

    12/5/24 4:30:00 PM ET
    $CSBR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CSBR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Breitfeld Philip P. disposed of 4,150 shares, decreasing direct ownership by 42% to 5,717 units (SEC Form 4)

    4 - CHAMPIONS ONCOLOGY, INC. (0000771856) (Issuer)

    4/2/25 4:20:36 PM ET
    $CSBR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Director Breitfeld Philip P.

    4 - CHAMPIONS ONCOLOGY, INC. (0000771856) (Issuer)

    11/18/24 12:14:09 PM ET
    $CSBR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Director Sidransky David

    4 - CHAMPIONS ONCOLOGY, INC. (0000771856) (Issuer)

    11/18/24 11:47:41 AM ET
    $CSBR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CSBR
    Financials

    Live finance-specific insights

    View All

    Champions Oncology Reports Quarterly Revenue of $13.5 Million Adjusted EBITDA of $1.1 Million

    HACKENSACK, NJ / ACCESSWIRE / December 11, 2024 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, today announced its financial results for its second quarter of fiscal 2025, ended October 31, 2024.Second Quarter and Recent Highlights:Total revenue increased 17% to $13.5 millionGross profit of $6.1 million; margin of 45%Net income of approximately $730,000Adjusted EBITDA of $1.1 millionDevelopment of new data revenue streamFirst Half 2025 Highlights:Total revenue increased 14% to $27.6 millionGross profit of $13.1 million; margin of 47%Net income of $2.1 millionAdjusted EBITDA of $3.2 millionRonni

    12/11/24 4:00:00 PM ET
    $CSBR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Champions Oncology to Announce Second Quarter Financial Results on Wednesday, December 11, 2024

    HACKENSACK, NJ / ACCESSWIRE / December 5, 2024 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, will report its financial and operational results for the second quarter ended October 31, 2024, on Wednesday, December 11, 2024, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M. EST (1:30 P.M. PST). To join the call dial 888-506-0062 (Domestic) or 973-528-0011 (International) and enter the access code 710610. A replay of the call will be available by dialing 877-481-4010 (Domestic) or 919-882-2331 (International) and entering passcode: 51750, or

    12/5/24 4:30:00 PM ET
    $CSBR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Champions Oncology Reports Quarterly Revenue of $14.1 Million Adjusted EBITDA of $2.0 Million

    HACKSENSACK, NJ / ACCESSWIRE / September 11, 2024 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, today announced its financial results for its first quarter of fiscal 2025, ended July 31, 2024.First Quarter Highlights:Total revenue increased 12% to $14.1 millionMargin improved to 50%Adjusted EBITDA of $2.0 millionNet income of $1.3 millionRonnie Morris, CEO of Champions, commented, "As outlined on our year-end earnings call, we're cautiously optimistic that we've weathered the worst of the business downturn and we're poised to emerge leaner and stronger. Our first quarter's performance provided

    9/11/24 4:00:00 PM ET
    $CSBR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CSBR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Champions Oncology Inc.

    SC 13G/A - CHAMPIONS ONCOLOGY, INC. (0000771856) (Subject)

    11/14/24 9:53:10 AM ET
    $CSBR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13D/A filed by Champions Oncology Inc. (Amendment)

    SC 13D/A - CHAMPIONS ONCOLOGY, INC. (0000771856) (Subject)

    5/6/24 7:46:06 PM ET
    $CSBR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Champions Oncology Inc.

    SC 13G - CHAMPIONS ONCOLOGY, INC. (0000771856) (Subject)

    2/12/24 9:12:00 PM ET
    $CSBR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CSBR
    Leadership Updates

    Live Leadership Updates

    View All

    Champions Oncology Enhances Clinical Bioanalytical Services Portfolio with New Technology and Additional Leadership

    HACKENSACK, NJ / ACCESSWIRE / January 8, 2025 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading technology-enabled oncology research organization with specialty testing services, is excited to announce significant advancements in its bioanalytical services portfolio, specifically, expanding its capabilities with the integration of multiple global Cytek Aurora flow cytometers and the appointment of Troy Tremaine, MBA, to spearhead Bioanalytical Commercial Strategy.The addition of Cytek Aurora instruments elevates Champions' service offerings, building on its already competitive spectral and conventional flow cytometry capabilities. The continued investment in this clinical portfolio of serv

    1/8/25 8:00:00 AM ET
    $CSBR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Champions Oncology Announces the Addition of Brady Davis as President

    HACKENSACK, NJ / ACCESSWIRE / October 17, 2023 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, has appointed Brady Davis as President to continue to develop new strategic initiatives to drive accelerated growth."We are thrilled to have Brady join the already incredibly talented team here at Champions Oncology. Brady has deep healthcare, data and oncology-specific experience and has a proven track record of building products and solutions that align with customer needs," stated Ronnie Morris, CEO of Champions Oncology.Mr. Davis brings more than 25 years of international experience leading medical

    10/17/23 8:30:00 AM ET
    $CSBR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Champions Oncology Announces Addition to Board of Directors

    HACKENSACK, NJ / ACCESSWIRE / February 22, 2021 / Champions Oncology, Inc. (NASDAQ:CSBR) a leading global oncology technology solutions provider transforming drug discovery through innovative pharmacology, biomarker, and data platforms, is pleased to announce the appointment of Rob Brainin to its Board of Directors. Rob is an experienced global life sciences and healthcare executive with more than 15 years of experience. His appointment will help guide the company's efforts to accelerate the development of its data platform for use in drug discovery. The Company also announced the resignation of current board member Abba Poliakoff. Joel Ackerman, Chairman of the Board of Directors commented

    2/22/21 9:00:00 AM ET
    $CSBR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care